<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364969">
  <stage>Registered</stage>
  <submitdate>12/09/2013</submitdate>
  <approvaldate>16/09/2013</approvaldate>
  <actrnumber>ACTRN12613001029785</actrnumber>
  <trial_identification>
    <studytitle>Calcium balance during citrate hemodialysis</studytitle>
    <scientifictitle>Comparison of calcium mass balance with two different ionized calcium target ranges during hemodialysis with regional citrate anticoagulation</scientifictitle>
    <utrn>U1111-1147-9668</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hemodialysis</healthcondition>
    <healthcondition>Kidney disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single hemodialysis with regional citrate anticoagulation; target ionized calcium range 0.95 - 1.05 mmol/l
</interventions>
    <comparator>Single hemodialysis with regional citrate anticoagulation; target ionized calcium range 1.1 - 1.2 mmol/l</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>calcium mass balance; calculated as (volume * concentration of calcium in infusion) - (spent dialysate volume * calcium concentration in dialysate); total calcium in dialysate measured with standard laboratory test</outcome>
      <timepoint>during hemodialysis</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>blood ionized calcium &lt; 0.9 mmol/l; determined with point-of-care analyzer</outcome>
      <timepoint>during hemodialysis</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in intact parathiroid hormone (serrum assay)</outcome>
      <timepoint>during hemodialysis</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>adult patients, needing hemodialysis with regional citrate anticoagulation due to increased bleeding risk</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>known intolerance of citrate anticoagulation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/10/2013</anticipatedstartdate>
    <actualstartdate>14/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>12/01/2016</actualenddate>
    <samplesize>30</samplesize>
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>14/01/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>University Medical Center Ljubljana, Dept. of Nephrology</primarysponsorname>
    <primarysponsoraddress>Zaloska 7
1000 LJubljana</primarysponsoraddress>
    <primarysponsorcountry>Slovenia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Javna agencija za raziskovalno dejavnost RS</fundingname>
      <fundingaddress>Bleiweisova cesta 30
1000 Ljubljana</fundingaddress>
      <fundingcountry>Slovenia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To compare calcium mass balance and effect on iPTH during regional citrate anticoagulation in hemodialysis with two different target ranges for ionized calcium</summary>
    <trialwebsite />
    <publication>- Gubensek J, Orsag A, Ponikvar R, Buturovic-Ponikvar J. Calcium Mass Balance during Citrate Hemodialysis: A Randomized Controlled Trial Comparing Normal and Low Ionized Calcium Target Ranges. PLoS One. 2016 Dec 28;11(12):e0168593. doi: 10.1371/journal.pone.0168593
- J Gubensek, A Orsag, R Ponikvar, A Jerman and J Buturovic-Ponikvar. CALCIUM MASS BALANCE DURING CITRATE HEMODIALYSIS: A RANDOMIZED CONTROLLED TRIAL COMPARING NORMAL AND LOW IONIZED CALCIUM TARGET RANGE. Oral presentation at 53rd ERA-EDTA Congress, May 21st-24th, 2016, Vienna, Austria; Published in Nephrology Dialysis Transplantation Volume 31, Issue suppl 1, pp. i66-i67, doi: 10.1093/ndt/gfw145.03</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National medical ethics committee</ethicname>
      <ethicaddress>prof. Joze Trontelj
Inst. za klinicno nevrofiziologijo
UKC Ljubljana
Zaloska 7
1000 LJubljana</ethicaddress>
      <ethicapprovaldate>19/03/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>4/03/2012</ethicsubmitdate>
      <ethiccountry>Slovenia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jakob Gubensek</name>
      <address>University Medical Center Ljubljana
Dept. of Nephrology
Zaloska 7
1000 Ljubljana</address>
      <phone>+386 1 522 3112</phone>
      <fax />
      <email>jakob.gubensek@kclj.si</email>
      <country>Slovenia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jakob Gubensek</name>
      <address>University Medical Center Ljubljana
Dept. of Nephrology
Zaloska 7
1000 Ljubljana</address>
      <phone>+386 1 522 3112</phone>
      <fax />
      <email>jakob.gubensek@kclj.si</email>
      <country>Slovenia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jakob Gubensek</name>
      <address>University Medical Center Ljubljana
Dept. of Nephrology
Zaloska 7
1000 Ljubljana</address>
      <phone>+386 1 522 3112</phone>
      <fax />
      <email>jakob.gubensek@kclj.si</email>
      <country>Slovenia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>